LIAM DONOVAN: Open Payments
NPI 1083452502 · GLEN BURNIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,548 in 155 payments from 20 companies in 2025. Trend: 2023 $0 · 2024 $1,129 · 2025 $3,548
Food & beverage: $3,362Education: $186
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 15 | $564 |
| E.R. Squibb & Sons, L.L.C. | 15 | $425 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $396 |
| Lundbeck LLC | 22 | $350 |
| Neurocrine BioSciences, Inc. | 14 | $277 |
| Alkermes, Inc. | 12 | $246 |
| Otsuka America Pharmaceutical, Inc. | 4 | $210 |
| Janssen Pharmaceuticals, Inc | 6 | $174 |
| ABBVIE INC. | 14 | $135 |
| Vanda Pharmaceuticals Inc. | 5 | $118 |
Products named: REXULTI, COBENFY, CAPLYTA, INGREZZA, ARISTADA, AUSTEDO XR, UZEDY, INVEGA SUSTENNA.
Industry payments across MD — which companies pay providers there.
